The race is on. Across the globe, researchers, scientists and CEOs are developing more than 160 vaccines, all taking aim at COVID-19.
Research and testing timelines have been slashed from years to months.
And today, I want to give you a sneak preview of one of the most promising vaccines you probably haven’t heard about yet.
The company is called COVAXX — a spinout of United Biomedical, a 30+ year-old vaccine company that has a proven track record of manufacturing 500 million vaccine doses per year (5 billion+ over the last decade).
Most importantly, the preclinical data on this vaccine is amazing, better than anything else I’ve seen. As we hit over 17 million people infected, and more than 668,000 COVID-related deaths across the globe, nothing will return us to normalcy until a safe and effective vaccine is in place!
Want to learn more about COVAXX? Join me, Tony Robbins, and the co-CEOs of COVAXX NEXT WEDNESDAY for a detailed Webinar at 1pm PT / 4pm ET to learn more… Bring your friends and family: you will want to be among the first to know about this vaccine and its extraordinary potential.
First, a disclosure: I’ve personally been working on COVAXX non-stop since March. While I normally focus on a half-dozen companies (XPRIZE, Singularity University, BOLD Capital, Abundance, FutureLoop and more), the magnitude of COVID-19 and the power of this vaccine is so compelling, that I’ve put almost everything else on hold to get this technology to the finish line…
What you should know about COVAXX, what gets me personally excited:
(1) No LIVE VIRUS used. The COVAXX vaccine is safe for both patients and the environment, posing no biohazard risk, as no live virus is used in its design or production.
(2) This vaccine generates Super-High Antibody levels… 400 times higher than convalescent plasma (that is, the plasma of those who have recovered from the virus and whose immune systems have naturally generated antibodies to fight it).
(3) These antibodies are POWERFUL. We measure effectiveness by the “neutralizing titers” of a vaccine… the ability of antibodies to knock out the SARS-CoV-2 virus. By comparison, the Oxford AstraZeneca vaccine has a neutralizing titer of 40, while Moderna is in the range of 500–1000. Amazingly, the COVAXX vaccine has a neutralizing titer of >32,000.
(4) The COVAXX vaccine is manufacturable. One concern about numerous other vaccine companies is their ability to actually manufacture a vaccine at scale. For many, this is their first time with an unproven supply chain. For COVAXX, the United Biomedical platform has cheaply and reliably manufactured >5 billion doses over the past decade. And, because it is a synthetic vaccine, it needs no extreme refrigeration to store or transport.
(5) Effective in the elderly. Make no mistake, while COVID-19 impacts all of us, the risk of severe illness increases as we age. Yet many of today’s proposed vaccines may be too risky or not offer adequate protection for older adults. One aspect of the COVAXX vaccine platform is that in human clinical trials for an Alzheimer’s vaccine, it showed the ability to induce high-volume generation of antibodies in 98% of elderly patients. When targeting COVID-19, these figures would be tremendous!
(6) First to reach 100 million patients : COVAXX has committed its manufacturing facilities to produce 100 million doses by early Q1 2021, with the further objective of delivering up to 1 billion doses by the end of 2021.
Across the board, there’s a lot to be excited about and I’d LOVE to share it with you.
So JOIN TONY ROBBINS & ME as we interview the Co-CEOs (Mei Mei Hu & Lou Reese) about COVAXX, the Vaccine and much more.
A LIVE Q&A will follow the webinar.
Webinar Date: NEXT WEDNESDAY, August 5 at 1pm PT (4pm ET).
Click HERE to register for this free webinar, and we look forward to seeing you there!
Originally published at https://www.diamandis.com.